Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1972 1
1982 1
1983 1
1984 1
1985 1
1986 1
1987 2
1988 1
1989 1
1990 3
1991 2
1993 2
1994 3
1995 1
1996 1
1997 4
1998 2
1999 2
2000 4
2001 3
2002 3
2003 5
2004 3
2005 1
2006 2
2007 1
2008 4
2009 3
2010 3
2011 12
2012 10
2013 9
2014 8
2015 8
2016 5
2017 4
2018 5
2019 10
2020 17
2021 20
2022 23
2023 27
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Results by year

Filters applied: . Clear all
Page 1
Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV).
Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, Böckle BC, Caproni M, Caux F, Chandran NS, Cianchini G, Daneshpazhooh M, De D, Didona D, Di Zenzo GM, Dmochowski M, Drenovska K, Ehrchen J, Goebeler M, Groves R, Günther C, Horvath B, Hertl M, Hofmann S, Ioannides D, Itzlinger-Monshi B, Jedličková J, Kowalewski C, Kridin K, Lim YL, Marinovic B, Marzano AV, Mascaro JM, Meijer JM, Murrell D, Patsatsi K, Pincelli C, Prost C, Rappersberger K, Sárdy M, Setterfield J, Shahid M, Sprecher E, Tasanen K, Uzun S, Vassileva S, Vestergaard K, Vorobyev A, Vujic I, Wang G, Wozniak K, Yayli S, Zambruno G, Zillikens D, Schmidt E, Joly P. Borradori L, et al. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1689-1704. doi: 10.1111/jdv.18220. Epub 2022 Jun 29. J Eur Acad Dermatol Venereol. 2022. PMID: 35766904 Free article.
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. ...In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathiopri …
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membr …
Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment.
Bernard P, Antonicelli F. Bernard P, et al. Am J Clin Dermatol. 2017 Aug;18(4):513-528. doi: 10.1007/s40257-017-0264-2. Am J Clin Dermatol. 2017. PMID: 28247089 Review.
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in Western countries, and typically affects the elderly. ...In the past decade, potent topical corticosteroids have emerged as an effective and safe first-line treatment for BP, bu …
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in Western countries, and typically affe …
Eosinophilic Dermatoses: Recognition and Management.
Marzano AV, Genovese G. Marzano AV, et al. Am J Clin Dermatol. 2020 Aug;21(4):525-539. doi: 10.1007/s40257-020-00520-4. Am J Clin Dermatol. 2020. PMID: 32394361 Review.
We review clinicopathologic features and management of diseases belonging to each group, particularly: (1) pemphigus herpetiformis and atopic dermatitis as prototypes of the epidermal group; (2) bullous pemphigoid as prototypic eosinophilic dermatosis of the dermal- …
We review clinicopathologic features and management of diseases belonging to each group, particularly: (1) pemphigus herpetiformis and atopi …
Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P, Xu W, Zhang L. Cao P, et al. Front Immunol. 2022 Jun 13;13:928621. doi: 10.3389/fimmu.2022.928621. eCollection 2022. Front Immunol. 2022. PMID: 35769474 Free PMC article.
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. ...OBJECTIVE: To systematically review the rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid. METHODS: A PubM …
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease of the skin. ...OBJECTIV …
Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.
Wilson SE. Wilson SE. J Ocul Pharmacol Ther. 2023 Apr;39(3):191-206. doi: 10.1089/jop.2022.0174. Epub 2023 Mar 6. J Ocul Pharmacol Ther. 2023. PMID: 36877777 Free PMC article. Review.
These include scarring fibrosis associated with corneal trauma, chemical burns, infections, surgical complications, and persistent epithelial defects, as well as conjunctival fibrotic diseases, such as ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Research is …
These include scarring fibrosis associated with corneal trauma, chemical burns, infections, surgical complications, and persistent epithelia …
Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis.
Marzano AV, Maronese CA, Genovese G, Ferrucci S, Moltrasio C, Asero R, Cugno M. Marzano AV, et al. J Allergy Clin Immunol. 2022 Apr;149(4):1137-1149. doi: 10.1016/j.jaci.2022.02.007. J Allergy Clin Immunol. 2022. PMID: 35396080 Review.
A focus on its main differential diagnoses is provided, that is, chronic spontaneous urticaria, bullous pemphigoid, IgA (Henoch-Schonlein purpura) and IgM/IgG immune complex vasculitis, lupus erythematous tumidus, Wells syndrome, erythema multiforme, cutaneous masto …
A focus on its main differential diagnoses is provided, that is, chronic spontaneous urticaria, bullous pemphigoid, IgA (Henoc …
Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Muntyanu A, et al. J Cutan Med Surg. 2021 Jan-Feb;25(1):59-76. doi: 10.1177/1203475420943260. Epub 2020 Aug 3. J Cutan Med Surg. 2021. PMID: 32746624 Review.
However, they can also lead to immune intolerance and immune-related adverse event (irAEs) that are new and specific to these therapies. Cutaneous irAEs are the most common, arising in up to 34% of patients on PD-1 inhibitors and 43% to 45% on CTLA-4 inhibitors. ...For ins …
However, they can also lead to immune intolerance and immune-related adverse event (irAEs) that are new and specific to these therapies …
Biological treatment for bullous pemphigoid.
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Oren-Shabtai M, et al. Front Immunol. 2023 Apr 27;14:1157250. doi: 10.3389/fimmu.2023.1157250. eCollection 2023. Front Immunol. 2023. PMID: 37180101 Free PMC article.
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease. ...No adverse events were reported. CONCLUSIONS: Efficient and safe novel therapies can be considered in recalcitrant steroid-dependent BP non-responsive to …
BACKGROUND: Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous disease. ...No adverse events we …
Management of Coexisting Bullous Pemphigoid and Psoriasis: A Review.
Hsieh CY, Tsai TF. Hsieh CY, et al. Am J Clin Dermatol. 2022 Nov;23(6):869-879. doi: 10.1007/s40257-022-00719-7. Epub 2022 Aug 14. Am J Clin Dermatol. 2022. PMID: 35964277 Review.
Psoriasis in an immune-mediated inflammatory disease and is associated with increased risk of various comorbidities, especially autoimmune bullous diseases. However, the optimal management of coexisting psoriasis and bullous pemphigoid (BP) is not known. ...
Psoriasis in an immune-mediated inflammatory disease and is associated with increased risk of various comorbidities, especially autoimmune …
Bullous pemphigoid: clinical practice guidelines.
Fuertes de Vega I, Iranzo-Fernández P, Mascaró-Galy JM. Fuertes de Vega I, et al. Actas Dermosifiliogr. 2014 May;105(4):328-46. doi: 10.1016/j.ad.2012.10.022. Epub 2013 Mar 26. Actas Dermosifiliogr. 2014. PMID: 23540594 Free article. Review. English, Spanish.
Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease in which autoantibodies are directed against components of the basement membrane. ...These advances include new diagnostic techniques, such as enzyme-linked immunosorbent assay for BP180 an …
Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease in which autoantibodies are directed against comp …
201 results